NAFLD is seriously affecting the general health due to its liver-related consequences (liver cirrhosis and hepatocellular carcinoma) and its great risk for extra-hepatic chronic complications (T2DM, MS, and cardiovascular disease).[1] The role of incretin-based therapies as a potential treatment for NAFLD has attracted much attention. The gene discussed is GCG; the disease is hepatocellular carcinoma.